Remove 2001 Remove Pharmaceuticals Remove Regulations
article thumbnail

Can Europe become a major player in cell and gene therapy?

Drug Discovery World

A new report by Charles River Associates for the European Federation of Pharmaceutical Industries and Associations (EFPIA has revealed that Europe is falling behind the US and Asia in its pharmaceutical R&D investment, particularly when it comes to Advanced Therapies Medicinal Products (ATMPs) like tissue, gene and cell therapies. .

Therapies 245
article thumbnail

Report: huge inequalities in access to myeloma clinical trials in Europe 

Drug Discovery World

The MPE report presents clinical trial analytics, looking at the number of clinical trials held in CEE countries between 1 January 2001 and 28 September 2020. Most myeloma clinical trials in CEE are run by the pharmaceutical industry (around 80%) given their ability to invest in and finance such research . The findings .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Preparing the next generation of drug discovery scientists

Drug Discovery World

This ranges from understanding disease processes and identifying possible drug targets, to organising testing, rolling out clinical trials, negotiating complex regulations and licensing and finally, treating patients. Providing a broad view.

article thumbnail

Article EMA Thank You European Commission reveals action plan to address medicines shortages

Agency IQ

The Pharmaceutical Group of the European Union (PGEU) conducted a survey finding shortages worsened in 2022 compared to 2021, with most European countries reporting worsening. The Pharmaceutical Strategy document notes that Covid-19 just compounded medicines shortages that had already impacted patient health and the E.U. wide level.

article thumbnail

Preliminary Injunction Decision in Chambers of Commerce Case Provides First Insights Into Merits of Medicare Negotiations Cases

FDA Law Blog: Biosimilars

Engler , a 2001 decision by the Sixth Circuit Court of Appeals. According to the court, the Constitution guarantees no right to conduct business with the government, so the consequences of that participation can be “conditioned by regulation” without being considered unconstitutional. See Order at 15, 21.

article thumbnail

Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions

The Pharma Data

14, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals, Inc. Tonix Pharmaceuticals Holding Corp. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval, and commercialization of new products. CHATHAM, N.J., Holding Corp. 175:1091-1101 (1992) 2 Karpusas, M et al.,

article thumbnail

Article EMA Thank You EMA publishes first electronic Product Information as pilot progresses

Agency IQ

Summary of Product Characteristics and Package Leaflet), recommending that sponsors and regulators “explore the use of electronic media” to provide product information “in the future”. See also Article 11 of Directive 2001/83/EC.) If the ePI is approved by the regulator, then it will be made publicly available in the ePI database.